App-Based Study of Daily Life and Treatment in IgA Nephropathy
Follows adults with IgA nephropathy, a kidney disease, through symptoms, treatments and quality of life.
Plain-language title generated from the registry record
Registry title: A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
Key facts
- Where
- Boston, United StatesSee the site
Where in United States
- BostonBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06952426
- Record updated
- 17 June 2025
- Original description
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.Read full original descriptionShow less
A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
Inclusion: Diagnosis of IgAN, regardless of symptom or treatment history; Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age; US-based with a proficient understanding of and ability to read the English language.
Exclusion: None.